Express Mail No.: EV053213585US
Date of Deposit: February 6, 2002

We claim:

1. A substantially pure or isolated oligodeoxynucleotide of at least about 16 nucleotides in length comprising a sequence represented by the following formula:

5' $X_1X_2X_3$ Pu_1 Py_2 CpG Pu_3 Py_4 $X_4X_5X_6(W)_M$ $(G)_N$-3'

wherein the central CpG motif is unmethylated, Pu is a purine nucleotide, Py is a pyrimidine nucleotide, X and W are any nucleotide, M is any integer from 0 to 10, and N is any integer from 4 to 10.

2. The oligodeoxynucleotide of claim 1, wherein N is about 6.

3. The oligodeoxynucleotide of claim 1 wherein Pu Py CpG Pu Py comprises phosphodiester bases.

4. The oligodeoxynucleotide of claim 3 wherein Pu_1 Py_2 CpG Pu_3 Py_4 are phosphodiester bases.

5. The oligodeoxynucleotide of claim 3, wherein $X_1X_2X_3$ and $X_4X_5X_6(W)_M$ $(G)_N$ comprise phosphodiester bases.

6. The oligodeoxynucleotide of claim 3, wherein $X_1X_2X_3$ comprises one or more phosphothioate bases.

7. The oligodeoxynucleotide of claim 3, wherein $X_4X_5X_6(W)_M$ $(G)_N$ comprises one or more phosphothioate bases.

8. The oligodeoxynucleotide of claim 1, wherein $X_1X_2X_3$ Pu Py and Pu Py $X_4X_5X_6$ are self complementary.

9. The oligodeoxynucleotide of claim 1, wherein $X_1X_2X_3$ AND $X_4X_5X_6$ are self complementary.

Express Mail No.: EV053213585US
Date of Deposit: February 6, 2002

10. The oligodeoxynucleotide of claim 1, wherein Pu Py and Pu Py are self complementary.

11. The oligodeoxynucleotide of claim 1, wherein the oligodeoxynucleotide comprises the sequence

5'-X_1X_2TGCATCGATGCAGGGGGG-3' (SEQ ID NO:12);
5'- X_1X_2TGCACCGGTGCAGGGGGG-3' (SEQ ID NO:13);
5'- X_1X_2TGCGTCGACGCAGGGGGG-3'; (SEQ ID NO:)15;
5'- X_1X_2TGCGTCGATGCAGGGGGG -3'; (SEQ ID NO:16);
5'- X_1X_2TGCGCCGGCGCAGGGGGG-3;'(SEQ ID NO:17);
5'- X_1X_2TGCGCCGATGCAGGGGGG-3'(SEQ ID NO:18);
5'- X_1X_2TGCATCGACGCAGGGGGG-3'(SEQ ID NO:19); or.
5'- X_1X_2TGCGTCGGTGCAGGGGGG-3'(SEQ ID NO:20),
wherein X_1 is a G or not base and X_2 is a G or no base.

12. The oligodeoxynucleotide of claim 1, comprising any one of
GGTGCATCGATGCAGGGGGG (SEQ ID NO: 1);
AAGGTCAACG TTGAAAAAAA (SEQ ID NO: 35);
GGTGCATCGATGCAGGGGGG (SEQ ID NO: 1);
GGTGCATCGATGCAGGGGGG (SEQ ID NO: 1);
GGTGCGTCGACGCAGGGGGG SEQ ID NO: 31);
GGTGCGTCGATGCAGGGGGG (SEQ ID NO: 7);
GGTGCACCGGTGCAGGGGGG (SEQ ID NO: 2);
GTCGACGTCGAC (SEQ ID NO: 54);
GGTGCATCGATGCAGGGGG (SEQ ID NO: 73);
GGCGTCGACG GGG (SEQ ID NO: 74);
GGTGCATCGATGCGAGAGA (SEQ ID NO: 87);
TCGGATGTTCTC (SEQ ID NO: 113), or
GGTCCATCGATCCAGGGGGG (SEQ ID NO: 138).

13. The oligodeoxynucleotide of any of claim 1, wherein the oligodeoxynucleotide is modified to prevent degradation.

Express Mail No.: EV053213585US
Date of Deposit: February 6, 2002

14. The oligodeoxynucleotide of claim 1, wherein the oligodeoxynucleotide has a phosphate backbone modification.

15. The oligodeoxynucleotide of claim 14, wherein the phosphate backbone modification is a phosphorothioate backbone modification.

16. The oligodeoxynucleotide of claim 1, wherein the oligodeoxynucleotide comprises about 100 nucleotides or less.

17. The oligodeoxynucleotide claim 16, wherein the oligodeoxynucleotide comprises about 50 nucleotides or less.

18. The oligodeoxynucleotide of claim 9, wherein the oligodeoxynucleotide comprises about 18 to about 30 nucleotides.

19. An oligodeoxynucleotide delivery complex comprising the oligodeoxynucleotide of claim 1 and a targeting moiety.

20. The oligodeoxynucleotide delivery complex of claim 19, wherein the targeting moiety is selected from the group consisting of a cholesterol, a virosome, a liposome, a lipid, and a target cell specific binding agent.

21. The oligodeoxynucleotide of delivery complex of claim 19, wherein the oligodeoxynucleotide and the targeting moiety are covalently linked.

22. A pharmacological composition comprising the oligodeoxynucleotide of claim 1 and a pharmacologically acceptable carrier.

23. A method of stimulating a cell of the immune system, comprising contacting the cell with an effective amount of the oligodeoxynucleotide of claim 1, thereby stimulating the cell.

24. The method of claim 23, wherein the cell is a monocyte, a natural killer cell, or a dendritic cell.

Express Mail No.: EV053213585US
Date of Deposit: February 6, 2002

25. A method of inducing an immune response in a subject, comprising administering a therapeutically effective amount of the oligodeoxynucleotide of claim 1, thereby inducing an immune response.

26. The method of claim 25, wherein the immune response comprises a cell-mediated immune response.

27. The method of claim 25, wherein the immune response comprises a natural killer cell, or a dendritic cell response.

28. The method of any of claims 25, wherein the oligodeoxynucleotide induces production of a cytokine in the subject.

29. The method of claim 25, wherein the cytokine is interferon gamma (IFN-γ).

30. The method of claim 25, wherein the cytokine is interferon alpha (IFN-α).

31. The method of claim 25, wherein the cytokine is interferon inducible protein 10 (IP-10).

32. The method of claim 25, wherein the cytokine is interleukin 10 (IL-10).

33. The method of claim 25, wherein the immune response comprises activating or inducing maturation of a cell of the immune system, and wherein the cell of the immune system is an NK cell, a monocyte, a dendritic cell precursor or a dendritic cell.

34. The method of claim 33, wherein the immune response comprises activating a cell of the immune system, and wherein the cell of the immune system is an NK cell.

Express Mail No.. EV053213585US
Date of Deposit: February 6, 2002

35. The method of claim 33, wherein the immune response comprises activating a cell of the immune system, and wherein the cell of the immune system is a monocyte.

36. The method of claim 33, wherein the immune response comprises inducing maturation of a cell of the immune system, and wherein the cell of the immune system is a dendritic cell.

37. The method of claim 36, wherein the dendritic cell is a plasmacytoid dendritic cell.

38. The method of claim 25, wherein the immune response is an immunotherapeutic response against a neoplasm.

39. The method of claim 38, wherein the neoplasm is a solid tumor.

40. The method of claim 38, further comprising administering an anti-neoplasic agent to the subject.

41. The method of claim 36, wherein the anti-neoplastic agent is a chemotherapeutic agent or radiation.

42. A method of inducing of an immune response to prevent or ameliorate an allergic reaction, comprising administering a therapeutically effective amount of the oligodeoxynucleotide of claim 1 to a subject having or subject to having an allergic reaction, wherein administration of the oligodeoxynucleotide treat, prevents or ameliorates the allergic reaction.

43. The method of claim 42, further comprising administering an anti-allergenic agent.

44. The method of claim 42, wherein the allergic reaction is an asthmatic response to an allergen.

45. A method of enhancing the efficacy of a vaccine in a subject, comprising administering the oligodeoxynucleotide of claim 1 in combination with the vaccine to the subject, thereby enhancing the efficacy of the vaccine.

46. The method of claim 45, wherein the vaccine is a live, attenuated, or heat-killed vaccine.

47. The method of claim 45, wherein the vaccine is a viral vaccine.

48. A method of preventing or treating a disease associated with an immune system in a subject, comprising administering a therapeutically effective amount of the oligodeoxynucleotide of claim 1 to the subject, wherein administration of the oligodeoxynucleotide treats or prevents the disease associated with the immune system.

49. The method of claim 48, wherein the disease associated with the immune system is an autoimmune disorder.

50. The method of claim 48, wherein the disease associated with the immune system is an immune system deficiency.

51. The method of claim 48, further comprising administering an anti-infectious agent.

52. A method of inducing an immune response against an infectious agent, comprising administering the oligonucleotide of claim 1 to a subject infected with the infectious agent, thereby inducing an immune response against the infectious agent.

53. The method of claim 52, wherein the infectious agent is leishamanaisis.

54. The method of claim 52, wherein the infectious agent is a fungus, bacteria, or a virus.

55. The method of claim 52, further comprising administering an anti-infectious agent.

56. The method of claim 52, wherein the anti-infectious agent is an antibiotic, an antiviral, or an anti-fungal agent.

57. A method for inducing an immune response in a subject, comprising

(a) contacting a monocyte or a dendritic cell precursor *in vitro* with the oligodeoxynucleotide of claim 1 to produce an activated antigen presenting cell, and

(b) administering the activated antigen presenting cell obtained in step (a) to the subject, thereby inducing an immune response.

58. A method for inducing an immune response in a subject, comprising

(a) contacting a monocyte or a dendritic cell precursor *in vitro* with the oligodeoxynucleotide of claim 1 to produce an activated antigen presenting cell, and

(b) contacting lymphocytes or natural killer cells *in vitro* with the activated antigen presenting cells to produce activated lymphocytes or activated natural killer cells; and

(c) administering the activated lymphocytes natural killer cells to the .subject, thereby inducing the immune response.

59. The method of claim 58, wherein the monocytes or a dendritic cell precursors contacted *in vitro* with the oligodeoxynucleotide